Ondansetron for the Treatment of Methamphetamine Dependence - 1
- Conditions
- Amphetamine-Related Disorders
- Registration Number
- NCT00040053
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.
- Detailed Description
This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 154
18 years of age. Treatment seeking for meth dependence.
Please contact site director for more details.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinicial improvement
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
South Bay Treatment Center
🇺🇸Chula Vista, California, United States
John A. Burns School of Medicine
🇺🇸Honolulu, Hawaii, United States
Powell Chemical Dependency Center
🇺🇸Des Moines, Iowa, United States
Matrix Institute on Addictions
🇺🇸Costa Mesa, California, United States
University of Missouri - Kansas City
🇺🇸Kansas City, Missouri, United States
University of Texas Health Science Center
🇺🇸Houston, Texas, United States